Geron's Total Assets for the quarter that ended in Dec. 2023 was $394.08 Mil.
During the past 12 months, Geron's average Total Assets Growth Rate was 238.60% per year.
During the past 3 years, the average Total Assets Growth Rate was -6.70% per year.
During the past 5 years, the average Total Assets Growth Rate was 10.00% per year.
During the past 10 years, the average Total Assets Growth Rate was 20.30% per year.
During the past 13 years, Geron's highest 3-Year average Total Assets Growth Rate was 109.60%. The lowest was -64.40%. And the median was -1.00%.
Total Assets is connected with ROA %. Geron's annualizedROA % for the quarter that ended in Dec. 2023 was -51.52%. Total Assets is also linked to Revenue through Asset Turnover. Geron's Asset Turnover for the quarter that ended in Dec. 2023 was 0.00.
Geron Total Assets Historical Data
The historical data trend for Geron's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Geron Annual Data
Trend
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Total Assets
165.52
270.73
226.03
190.58
394.08
Geron Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
Total Assets
190.58
424.88
415.30
413.02
394.08
Geron Total Assets Calculation
Total Assets are all the assets a company owns.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Geron's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note:
The Net Income data used here is four times the quarterly (Dec. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Geron's Asset Turnover for the quarter that ended in Dec. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Geron Total Assets Related Terms
Thank you for viewing the detailed overview of Geron's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses global rights to this drug. the company operates as a single segment, the development of therapeutic products for oncology.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GERN has been successfully added to your 